Pharma M&A Value Realization, How?
How do Pharma BD M&A teams ensure FULL value realization 3 years after ‘Day 1’?
This year’s JPMorgan Healthcare Conference predicts that in 2026, value creation from M&A is expected to explode! Pharma companies are preparing for patent cliffs through various forms of strategic acquisition (Cortes, et al., 2026).
In 2022, based on 10 years of ‘boots on the ground’ experience with operational teams sorting out post-acquisition Quality system and GxP IT chaos, I DEMANDED answers where there was NONE. The question of optimizing Quality Systems & GxP IT unit M&A value realization DROVE my doctoral literature research. The result was how to plan for SUCCESSFUL M&A in the Quality & GxP IT units.
Larger organizations use ‘standardized playbooks’ for acquisition integration. A one-size fits all strategy. The critical issue with Star Trek- like ‘Borging’ all acquisitions is the loss of innovation – in Quality Systems and GxP IT.
‘Borging’ acquisitions into the larger organization results in a M&A value LOSS from failure to capitalize on innovations.
In the rush to complete M&A integration, it’s important for the BD M&A planning teams to thoroughly assess the Quality & GxP IT units of the smaller, lean organization by teams with real world ‘boots on the ground’ experience.
Quality Systems & GxP IT are learned through years of real-life experience, not degrees, certificates, nor ‘book reading.’ Thus, discrete nuances of GxP operations and value are often missed by non-GxP experienced ‘MBA team’ based M&A plans. This is because business leaders overlook the critical areas of Quality & IT, decreasing value realization.
Cortes, M., Joyeux, S., Seshadri, A., Dohler, D. (2026). 2026 Global biopharmaceutical M&A and VC insights. Alvarez & Marsal.
#GuideStarMnA #DrShanOCL #trojans #usc #illini #lifesciences #acquisition